The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC333, for the treatment of IBD
Rehovot, Israel – November 30, 2021 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Biomica expects to initiate first-in-human, proof-of-concept study later this year
Rehovot & Haifa, Israel – October 27, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and Rambam Health Care Campus today announced the signing of a clinical trial agreement (CTA) for initiating a first in-human proof-of-concept (POC) for BMC128,
Rehovot, Israel – April 19, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday,
Biomica’s live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year
Rehovot, Israel – April 13, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Rehovot, Israel – January 21, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn’s & Colitis Congress® to be held from today January 21-24,
Rehovot, Israel – January 20, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference.
The company is advancing to scale-up and GMP batch production, to support anticipated first-in-man proof-of-concept clinical trials next year
Rehovot, Israel – October 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN),
Rehovot, Israel – September 9, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference.
Biomica’s, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year
Rehovot, Israel – September 8, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics,
The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials
Rehovot, Israel – January 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.